Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

Article Abstract:

Low-dose diuretics should be the first drug used to treat all patients with high blood pressure, according to a review of 42 clinical trials covering 192,478 patients. Low-dose diuretics were more effective in reducing the risk of coronary heart disease, heart attack, stroke, and congestive heart failure than other antihypertensive drugs such as calcium channel blockers, beta blockers, ACE inhibitors, and alpha blockers.

Author: Weiss, Noel S., Alderman, Michael H., Furberg, Curt D., Pahor, Marco, Psaty, Bruce M., Lumley, Thomas, Schellenbaum, Gina
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
Blood Pressure Preparations, Renal Diuretic Preparations, Evaluation, Cooking, Hypertension, Drug therapy, Antihypertensive drugs, Antihypertensive agents, Diuretics, Cookery for hypertensives

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and risk of rhabdomyolsis

Article Abstract:

The association between the use of cerivastatin sodium and the risk of rhabdomyolysis is reviewed in order to illustrate the operation and limitations of the current US post marketing safety-surveillance system. The findings suggest that compared with atrovastatin calcium, cerivastatin monotherapy substantially increased the risk of rhabdomyolysis.

Author: Weiss, Noel S., Furberg, Curt D., Ray, Wayne A., Psaty, Bruce M.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
United States, Drugs, Adverse drug reactions, Rhabdomyolysis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Esterified estrogens and conjugated equine estrogens and risk of venous thrombosis

Article Abstract:

The risk of venous thrombosis among esterified estrogen users, conjugated equine estrogen users and nonusers are compared. The results revealed that conjugated equine estrogen associated with venous thrombotic risk needs to be replicated and may have implications for the choice of hormones in perimenopausal and postmenopausal women.

Author: Larson, Eric B., Weiss, Noel S., Psaty, Bruce M., Smith, Nicholas L., Heckbert, Susan R., Lumley, Thomas, Lemaitre, Rozen N., Rosendal, Frits R., Reiner, Alex P.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
Estrogen & Progestogen Preps, Health aspects, Thrombophlebitis, Postmenopausal women, Estrogen, Estrogens

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, Risk factors
Similar abstracts:
  • Abstracts: Cryptosporidiosis: an outbreak associated with drinking water despite state-of-the-art water treatment. American cutaneous leishmaniasis in U.S. travelers
  • Abstracts: Collagenase, its inhibitors, and decorin in the lower uterine segment in pregnant women. Onapristone and prostaglandin E2 induction of delivery in the rat in late pregnancy: a model for the analysis of cervical softening
  • Abstracts: Trial design and patient safety -- the debate continues. HIV infection--a new drug and new costs
  • Abstracts: Length of stay in home care before and after the 1997 Balanced Budget Act. Hospice use among Medicare managed care and fee-for-service patients dying with cancer
  • Abstracts: 'Services for people with dementia are not meeting families' expectations'
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.